NCT06285019 2024-02-29
Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular Carcinoma
Fudan University
Phase 2 Unknown
Clinical Trials
88 trialsNCT06269445 2024-02-21
The Efficacy and Safety of Lcaritin Combined With Bevacizumab and FOLFIRI in Treatment of Liver Metastases From Colorectal Cancer
Sir Run Run Shaw Hospital
Phase 4 Unknown
NCT05173298 2024-02-07
HCC
CHA University
Unknown
NCT06177288 2023-12-20
DEBIRI
Fudan University
Phase NA Unknown
NCT03451370 2023-11-29
COBRA
Istituto Oncologico Veneto IRCCS
Unknown
NCT04034459 2023-11-14
AIO-KRK-0116
Ludwig-Maximilians - University of Munich
Phase 2 Unknown
NCT04310176 2023-11-13
REVOLUTION
National Cancer Institute, Naples
Phase 2 Unknown
NCT05785325 2023-10-31
RC48-ADC Combined With Bevacizumab in HER2-positive Advanced Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT06060704 2023-10-11
Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT06039202 2023-09-15
Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer
Holy Stone Healthcare Co., Ltd
Phase 2 Unknown
NCT06003998 2023-08-22
INTERACT-II
Catharina Ziekenhuis Eindhoven
Phase 2 Unknown
NCT04262687 2023-08-18
POCHI
Federation Francophone de Cancerologie Digestive
Phase 2 Unknown
NCT04659382 2023-08-18
SIRTCI
Federation Francophone de Cancerologie Digestive
Phase 2 Unknown
NCT03950154 2023-08-01
Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Unknown
NCT04724239 2023-08-01
Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma
Sun Yat-sen University
Phase 2 Unknown
NCT05160896 2023-06-08
SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT05886465 2023-06-02
HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial
Sun Yat-sen University
Phase 2 Unknown
NCT05799820 2023-05-25
QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC
Qilu Pharmaceutical Co., Ltd.
Phase 2 Unknown
NCT05616390 2023-03-21
Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05760599 2023-03-08
Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T
Sun Yat-sen University
Phase 2 Unknown
NCT05163483 2023-03-06
Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT05745857 2023-02-27
SLURP
University Medical Center Groningen
Phase 2 Unknown
NCT04984980 2023-01-26
Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab in Unresectable Biliary Tract Cancer
Fudan University
Phase 2 Unknown
NCT05659290 2023-01-06
Alternating Treatment With Fruquintinib and Bevacizumab Plus Capecitabine as Maintenance Therapy After First-Line Treatment in Metastatic Colorectal Cancer
Nanfang Hospital, Southern Medical University
Phase 2 Unknown
NCT05588297 2022-10-20
Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver Metastases
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT05314101 2022-08-23
TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT01871571 2022-08-09
Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer
University of Southern California
Phase 2 Unknown
NCT04683965 2022-08-02
Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT04733963 2022-07-26
Fruquintinib Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT05438108 2022-06-29
SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab in First-line Treatment of mCRC
Huazhong University of Science and Technology
Phase 2 Unknown
NCT05396937 2022-05-31
Efficacy and Safety of T+A+RAD in HCC
Fudan University
Phase 2 Unknown
NCT05363722 2022-05-06
A Clinical Study to Observe the Effectiveness and Safety of IBI310, Bevacizumab Combined With Sintilimab in the Treatment of Advanced Hepatocellular Carcinoma
Shanghai Zhongshan Hospital
Phase 1 Unknown
NCT05103020 2021-11-02
Phase II Study Comparing Conversion Rate to Surgery With Hepatic Arterial Infusion Chemotherapy to Systemic Chemotherapy in Patients With Non Resectable Liver-only Colorectal Metastases
Yonsei University
Phase 2 Unknown
NCT04188145 2021-10-28
BEVAMAINT
Centre Hospitalier Universitaire Dijon
Phase 3 Unknown
NCT05068206 2021-10-20
A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Unknown
NCT02826837 2021-10-06
LEAC-102 for Advanced Colorectal Cancer
Taiwan Leader Biotech Corp.
Phase 1/2 Unknown
NCT05035381 2021-09-05
PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT03126071 2021-08-30
Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer
Jiangsu Cancer Institute & Hospital
Phase 2 Unknown
NCT04988191 2021-08-03
Toripalimab Plus Bevacizumab and Chemotherapy as Neoadjuvant Therapy in Advanced MSI-H or dMMR Colorectal Cancer
Peking University
Phase 1/2 Unknown
NCT04832776 2021-04-06
FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases
Fudan University
Phase 2 Unknown
NCT04739202 2021-03-29
IMMUNOGAST
Hospices Civils de Lyon
Phase 2 Unknown
NCT04788381 2021-03-09
The Effects of Preoperative Bevacizumab on Perioperative Complications
Second Affiliated Hospital, School of Medicine, Zhejiang University
Unknown
NCT04741165 2021-02-05
Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)
Taizhou Hanzhong biomedical co. LTD
Phase 2 Unknown
NCT01359397 2021-01-27
B-DOCT
The Netherlands Cancer Institute
Phase 2 Unknown
NCT04003792 2020-10-20
Treatment With Hepatic Arterial Infusion of Oxaliplatin in Combination With Systemic FOLFIRI Chemotherapy and Bevacuzimab in Patients With Liver-only Colorectal Liver Metastases (CRLM): Conversion to Complete Resection in Patients With Initially Inoperable Liver-only CRLM.
Rabin Medical Center
Phase 2 Unknown
NCT04527068 2020-09-17
BEVTOR
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT02226289 2020-09-02
BATTLE
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2 Unknown
NCT04525326 2020-08-25
Conversion Therapy of RAS/BRAF Wild-Type Right-sided Colon Cancer Patients With Initially Unresectable Liver Metastases
Fudan University
Phase 3 Unknown
NCT04213222 2020-08-11
ROBOT
Peking University People's Hospital
Unknown
NCT04397601 2020-05-21
ARBITRATION
National Cancer Institute, Naples
Unknown